Irving Weissman, MD – Ludwig Center for Cancer Stem Cell …

Dr. Weissmans laboratory is working on identifying and characterizing the progression of discrete changes, genetic and epigenetic, that leads to the generation of cancer stem cells (CSCs) from a variety of blood and solid tissue cancers. They have found a single molecular event present in all cancers studied to date that protects them from macrophages of the innate immune system.

Myelodysplastic Syndrome Investigators: Wendy Pang, Ravindra Majeti, Beverly Mitchell, Peter Greenberg, Jason Gotlib, Tena Cherry, and Irving Weissman

This group has proceeded with their work on myelodysplastic syndrome (MDS), a group of hematopoietic disorders characterized by ineffective and dysplastic myelopoiesis. Clinically, patients with MDS suffer from cytopenias and an increased risk for progression to acute myelogenous leukemia (AML).

Multiple Myeloma Investigators: Dongkyoon Kim, Bruno Medeiros, and Irving Weissman

In collaboration with Bruno Medeiros, MD, assistant professor of medicine (hematology), the laboratory is extending their work in multiple myeloma (MM), an incurable B-cell cancer. They have also investigated the coexistence of two tumor-initiating cell populations and their evolutionary hierarchy in a human myeloma cell line, RPMI 8226.

Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, and Lymphoma Investigators: Mark Chao, Max Jan, Ravindra Majeti, Ash Alizadeh, Sidd Jaiswal, and Irving Weissman

With a focus on the expression of CD47 on leukemia stem cells from AML and B-cell non-Hodgkin lymphoma (NHL) and its prognostic value, this group has made additional progress in the investigation of human AML and NHL in three major areas.

Follow this link:
Irving Weissman, MD - Ludwig Center for Cancer Stem Cell ...